TUSK says dermatology M&A stayed steady in H1 2026 despite healthcare slowdown

The adviser said add-on deals remain active, at least 25 private equity-backed platforms are nearing recapitalizations, and new state ownership laws are reshaping buyer appetite.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.